Prognosis for dogs with pituitary - dependent Cushing's treated medically is good with
a reported median survival rate of 2 years.
Stage 3 oral melanomas have
reported median survival times of approximately six months with treatment.
«Prior to this, the longest
reported median survival time of dogs with hemangiosarcoma of the spleen that underwent no further treatment was 86 days.
Not exact matches
MicroMentor
reports that participating businesses had a 75 percent increase in
median annual business sales and an 87 percent
survival rate year over year.
The
median survival period for patients receiving TAS - 102 was 7.1 months, compared to 5.3 months for patients taking a placebo, investigators
reported.
As
reported in 2015, the study met its primary endpoint after a
median follow up of 2.3 years, with ipilimumab significantly improving recurrence - free
survival.2 The drug was subsequently approved by the US Food and Drug Administration as adjuvant therapy for stage III melanoma.
Now, at 5.3 years
median follow up, the impact on overall
survival is
reported and represents a 28 % reduction of the relative risk of death (hazard ratio 0.72, p = 0.001).
«We
report much higher therapeutic efficacy in preclinical brain tumor models using the combination of both therapies, leading to an increase in
median survival,» Lowenstein says.
The data
reported today show continued increases in
median event - free
survival and muscle function scores as well as achievement of developmental milestones.
Regardless of the type of therapy, the prognosis has been a dismal
reported median overall
survival of 12 - 16 months and high rate of relapse within 1 year [1 - 3].
Retrospective case
reports suggest that adults may benefit from consolidation with allogeneic HSCT during their first CR following chemotherapy with one study observing a
median overall
survival of 38.5 months [5].
The
median overall
survival of patients in the Phase 1 resection injection study, where Toca 511 was injected into the wall of the resection cavity after removal of the tumor, exceeds historical controls across a variety of previously
reported clinical trials.
The most important measurement for CF Canada is the increase in
median age of
survival for those born with CF the current
median reported in the 2014 CF Canada Registry is 51.8 years of age versus 50.9 years of age in 2013 and 47.0 in 2008.
Recently, a
median survival time of 7 months was
reported for dogs receiving radiation therapy along with chemotherapy; whereas a combination of surgery and chemotherapy showed more encouraging
median survival rates of 235 - 366 days with up to 28 % surviving two years after diagnosis.
Median survival time after surgery alone is reported to be 2 - 3 months, with the addition of chemotherapy increasing the median survival time to 4 - 6 m
Median survival time after surgery alone is
reported to be 2 - 3 months, with the addition of chemotherapy increasing the
median survival time to 4 - 6 m
median survival time to 4 - 6 months.
Prognosis is variable, and the
median survival time is
reported to be 563 days for cats with heart failure.
According to some
reports, dogs treated with system chemotherapy showed a
median survival time of 5 months to 31 months.